Mitchell C. Posner to Disease-Free Survival
This is a "connection" page, showing publications Mitchell C. Posner has written about Disease-Free Survival.
Connection Strength
0.291
-
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
Score: 0.063
-
Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant. 2004 Oct; 18(5):502-12.
Score: 0.051
-
Non-resective ablation and liver transplantation in patients with cirrhosis and hepatocellular carcinoma (HCC): safety and efficacy. Am J Transplant. 2003 Mar; 3(3):312-7.
Score: 0.046
-
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. Arch Surg. 2001 Jul; 136(7):737-42; discussion 743.
Score: 0.041
-
Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2019 04; 269(4):589-595.
Score: 0.035
-
Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014 May; 259(5):960-5.
Score: 0.025
-
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb; 75(2):332-8.
Score: 0.021
-
Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol. 2000 Apr; 7(3):188-92.
Score: 0.009